@entity56 Reactions to XXXX : Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.

@entity1 @entity901 @entity56 @entity14
PURPOSE: We examined the clinical data of @entity1 treated with @entity901 to determine the risk factors of @entity901 -related @entity56 ( @entity56 ). In addition, we evaluated the efficacy of rechallenging @entity1 with HSRs with @entity901 using prophylactic agents or desensitization procedures. METHODS: This study consisted of 162 @entity1 with @entity14 (88 @entity1 and 74 @entity1 ) who were treated consecutively at the outpatient chemotherapy department at University Hospital, Kyoto Prefectural University of Medicine. @entity1 underwent chemotherapy, including @entity901 , between March 2006 and June 2012. We analyzed the @entity1 ' clinical backgrounds (eg, age, sex, performance status, disease stage, and allergic history) to uncover any connections to the development of @entity56 to @entity901 . In addition, we rechallenged 10 @entity1 who had @entity901 -related @entity56 using prophylactic agents or desensitization procedures. FINDINGS: Of 162 @entity1 , 28 (17.2%) developed @entity901 -related HSRs (16, 2, 9 and 1 @entity1 had grade 1, 2, 3, and 4 HSRs, respectively). The total cumulative dose of @entity901 at the onset of the @entity56 was 301 to 1126 mg/m(2) (median, 582 mg/m(2)), and the first reactions developed in these @entity1 after 5 to 17 infusions of @entity901 (median, 8 infusions). Logistic regression analysis indicated that sex (male: odds ratio = 3.624; 95% CI, 1.181-11.122; P = 0.024) and eosinophil count in peripheral blood (odds ratio = 35.118; 95% CI, 1.058-1166.007; P = 0.046) were independent variables for @entity901 -related HSRs. Rechallenging @entity1 with prophylactic agents was successful in 2 (28.6%) of 7 @entity1 who successfully completed their treatment. On the other hand, all 3 @entity1 rechallenged with @entity901 using a desensitization protocol successfully completed their treatment without new HSRs. IMPLICATIONS: In this retrospective study, we observed that being male and having higher counts of peripheral eosinophil could be predictors for @entity56 to @entity901 . In addition, this study confirms that @entity901 desensitization protocol allows @entity1 who developed HSRs to continue with their treatment. However, the optimum desensitization protocol for @entity901 administration in terms of tolerability and efficacy needs to be defined.
